BeOne Medicines (ONC) – Research Analysts’ Weekly Ratings Changes

Several analysts have recently updated their ratings and price targets for BeOne Medicines (NASDAQ: ONC):

• 7/27/2026 – BeOne Medicines was upgraded by Nomura to “strong-buy”.
• 7/23/2026 – BeOne Medicines had its price target raised by JPMorgan Chase & Co. from $415.00 to $425.00. They now have an “overweight” rating on the stock.
• 7/18/2026 – BeOne Medicines was upgraded by Wall Street Zen from “buy” to “strong-buy”.
• 7/17/2026 – BeOne Medicines had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 7/14/2026 – BeOne Medicines had its price target lowered by Barclays PLC from $409.00 to $403.00. They now have an “overweight” rating on the stock.
• 7/7/2026 – BeOne Medicines had its price target raised by Royal Bank Of Canada from $436.00 to $451.00. They now have an “outperform” rating on the stock.
• 7/7/2026 – BeOne Medicines had its price target raised by Truist Financial Corporation from $413.00 to $416.00. They now have a “buy” rating on the stock.
• 7/6/2026 – BeOne Medicines was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 7/3/2026 – BeOne Medicines was downgraded by Zacks Research from “strong-buy” to “hold”.
• 7/1/2026 – BeOne Medicines had its “market outperform” rating reaffirmed by Citizens Jmp. They now have a $396.00 price target on the stock.
• 6/28/2026 – BeOne Medicines was upgraded by Wall Street Zen from “buy” to “strong-buy”.
• 6/20/2026 – BeOne Medicines was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 6/4/2026 – BeOne Medicines was upgraded by Zacks Research from “hold” to “strong-buy”.
• 6/2/2026 – BeOne Medicines had its price target raised by Royal Bank Of Canada from $425.00 to $436.00. They now have an “outperform” rating on the stock.

Insiders Place Their Bets

In other news, COO Xiaobin Wu sold 1,484 shares of the company’s stock in a transaction dated Monday, June 8th. The shares were sold at an average price of $269.37, for a total value of $399,745.08. Following the completion of the sale, the chief operating officer directly owned 40 shares of the company’s stock, valued at approximately $10,774.80. This represents a 97.38% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO John Oyler sold 145,861 shares of the firm’s stock in a transaction dated Tuesday, July 14th. The stock was sold at an average price of $305.95, for a total value of $44,626,172.95. Following the transaction, the chief executive officer directly owned 8,122 shares in the company, valued at approximately $2,484,925.90. This represents a 94.73% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 343,360 shares of company stock worth $104,926,209. 6.19% of the stock is currently owned by company insiders.

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.